Terol LA 4 mg

✅ Active Ingredient Overview Table:

🌿 What is Tolterodine 4 mg ER (Terol LA)?

Terol LA contains Tolterodine, a competitive muscarinic receptor antagonist that reduces bladder muscle spasms. The extended-release formulation provides stable drug levels over 24 hours, improving symptoms of urinary urgency, frequency, and urge incontinence associated with overactive bladder.

Clinical studies demonstrate that once-daily Tolterodine ER 4 mg significantly reduces the number of incontinence episodes and improves quality of life. Additionally, the ER formulation shows fewer peak-related side effects like dry mouth and dizziness compared to immediate-release forms.

For full prescribing and safety information, refer to the FDA label for Detrol LA and the Drugs.com monograph. Further guidance is available through the NHS Medicines A–Z entry and the WHO Essential Medicines List.

🧬 Pharmacology & Mechanism of Action

Tolterodine blocks M2 and M3 receptors in the bladder detrusor muscle, decreasing involuntary contractions.

💡 Indications & Dosing

Take in the morning with or without food. Adjust dose to 2 mg ER in renal/hepatic impairment or CYP2D6 poor metabolizers.

⚠️ Warnings & Side Effects

Common:

• Dry mouth
• Headache, dizziness
• Constipation

Serious:

• Urinary retention
• Glaucoma exacerbation (narrow-angle)
• QT prolongation (rare)

Contraindicated in urinary retention, gastric retention, uncontrolled glaucoma, and severe hepatic impairment. Monitor for anticholinergic effects and adjust dose accordingly.

🏥 Storage Instructions

Store Terol LA at 20–25°C in its original blister pack. Protect from moisture and light. Keep out of reach of children.

🌐 Availability & Purchasing

• USA: Prescription-only (Detrol LA); branded and generic ER available.
• UK & EU: Prescription required; generic tolterodine ER available.
• Australia: Prescription and TGA approval needed.

Importing from India may lower costs; ensure compliance with local regulations and maintain a valid prescription.

🔗 Related Overactive Bladder Therapies

• Solifenacin 5 mg – M3-selective.
• Darifenacin 7.5 mg – M3-selective.
• Mirabegron 50 mg – β3-agonist.

🎥 Educational Video on Overactive Bladder Management

👨‍⚕️ Expert Insight: Dr. Kavita Desai, Urologist

“Extended-release tolterodine simplifies OAB management with once-daily dosing and improved tolerability. It’s a cornerstone therapy alongside behavioral interventions.”